CardioKinetix Starts China Trial of Heart Failure Device
October 24, 2014 at 05:52 AM EDT
CardioKinetix of California has enrolled the first ten patients in a China clinical trial of its first-in-class, minimally invasive medical device to treat heart failure. Following a heart attack, many patients suffer from shortness of breath because their hearts have become enlarged, reducing output. CardioKinetix's Parachute ® Ventricular Partitioning Device, inserted in the left ventricle via the femoral artery, partitions off the non-working section of the heart. The first China patients have been enrolled at Beijing's Peking University and Fu Wai Hospitals and at Shanghai Tenth People’s Hospital. More details.... Share this with colleagues: // //